S

Staedtisches Klinikum Karlsruhe | Medizinische Klinik III - Onkologie, Hämatologie, Infektiologie und Palliativmedizin

Research site

(Unclaimed)

Location

Moltkestraße 90, Karlsruhe, Baden-Württemberg, Germany

Site insights

Top conditions

Top treatments

Obinutuzumab

Lenalidomide

Etoposide

Dabrafenib

Trametinib

ABBV-383

Cytarabine

Dofetilide

Acalabrutinib

Sotalol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 12 total trials

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination...

Enrolling

Chronic Lymphocytic Leukemia

Drug: Venetoclax

Drug: Obinutuzumab

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with...

Active, not recruiting

Persistent Atrial Fibrillation

Device: FARAPULSE™ Pulsed Field Ablation (PFA) System

Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside o...

Enrolling

Multiple Myeloma

Drug: Carfilzomib

Drug: Etentamig

Locations recently updated

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is in...

Enrolling

Follicular Lymphoma (FL)

Drug: Obinutuzumab

Drug: Doxorubicin